This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters To the Editor

Reply to “Measuring Efficacy of Polypharmacy in Schizophrenic Inpatients”

Robert E. McCue, MD Rubina Waheed, MD Leonel Urcuyo, MD

Published: August 16, 2004

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: We welcome all comments on our report, the methodological limitations and tentative conclusions of which are outlined in the Discussion section of the article. A more careful reading of the Method section by Dr. Lindenmayer would have addressed his concern about our using only 1 admission of patients with multiple admissions. In fact, we used all discharges with the diagnosis of schizophrenia in 1995 and 2000. The number of unique patients in these samples was noted in the article.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 65

Quick Links: Schizophrenia and Schizoaffective Disorders

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...